Amylin And Takeda Discontinue Development Of
Links shared publicly online about this topic.
- 87total visits
Amylin And Takeda Discontinue Development Of
View full resource at pharmaceuticalonline.com
Most Recently Shared on August 8, 2011 at 5:22 pm By:
Amylin And Takeda Discontinue Development Of Pramlintide/Metreleptin Combination Treatment For Obesity Following... http://bit.ly/qIIhxi
Amylin Pharmaceuticals ª Investors ª Press Release
phx.corporate-ir.net — “Amylin Pharmaceuticals” View full resource at phx.corporate-ir.net
Most Recently Shared on August 6, 2011 at 11:29 am By:
eyeonfda Pharma and Health Lawyer
#Amylin and #Takeda Discontinue Development of Pramlintide/Metreleptin Combo Treatment for #Obesity http://ow.ly/5WH8d
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program - Drugs.com MedNews
drugs.com — “Collaboration Will Explore Potential of Other Assets to Address Obesity Epidemic OSAKA, Japan, Aug. 5, Amylin Pharmaceuticals, Inc. (Nasdaq AMLN) and Takeda Pha” View full resource at drugs.com
Most Recently Shared on August 5, 2011 at 1:06 pm By:
Drugs and Devices OW OW Health
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Fol... http://bit.ly/p1ft6q #drug
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program - Health News - redOrbit
redorbit.com — “SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- OSAKA, Japan, Aug. 5, 2011 -- Amylin Pharmaceuticals, Inc.” View full resource at redorbit.com
Most Recently Shared on August 5, 2011 at 4:53 am By:
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following... http://bit.ly/pnUdb1
Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development
news-medical.net — “Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced today that the companies have selected the combination treatment of pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, for advancement toward Phase 3 development. The decision to advance the program followed encouraging results from a 52-week blinded, placebo-controlled Phase 2 extension study. The pramlintide/metreleptin combination met the key target cri” View full resource at news-medical.net
Most Recently Shared on February 23, 2010 at 10:12 am By:
Obesity News: Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination th... http://twurl.nl/viyedg
Amylin and Takeda to develop and commercialize pharmaceutical products for obesity
news-medical.net — “Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.” View full resource at news-medical.net
Most Recently Shared on November 2, 2009 at 9:25 am By:
Stroke News: Amylin and Takeda to develop and commercialize pharmaceutical products for obesity: Am.. http://twurl.nl/jpo4qd
Amylin Strikes $1 Billion Deal with Takeda to Co-Develop Weight Loss Drugs | Xconomy
xconomy.com — “San Diego-based Amylin Pharmaceuticals, the dark horse in the race to develop a new breed of weight-loss drugs, has struck a partnership with Japan-based Takeda” View full resource at xconomy.com
Most Recently Shared on November 2, 2009 at 4:43 am By:
Luke Timmerman Health Communicator
Amylin strikes $1 billion deal with Takeda to co-develop weight loss drugs, resurrect leptin dud from Amgen pipeline. http://bit.ly/3ZagLJ
Yahoo! 404 - Page Not Found
us.rd.yahoo.com — “Yahoo! 404 - Page Not Found” View full resource at us.rd.yahoo.com
Most Recently Shared on November 2, 2009 at 1:56 am By:
Takeda, Amylin to co-develop obesity drugs (Reuters) http://bit.ly/46ztGi
Advertisement
